Endocrine Abstracts (2013) 32 P663 | DOI: 10.1530/endoabs.32.P663

Analysing by decade, testosterone undecanoat depot injectable does not increases prostate volume. Study during up to 6 years on hypogonadic patients

Dan Peretianu1, Mara Carsote2, Catalina Poiana2, Daniela Cristina Staicu1 & Matei Pisoschi3


1Societatea Civila Medicala Povernei, Bucharest, Romania; 2C.I. Parhon Institute of Endocrinology, Bucharest, Romania; 3Burghele Hospital, Bucharest, Romania.


Aim: Re-analyzing the effect of injectable testosterone undecanoat depot (TUD) in hypogonadic patients.

Material-method: i) Patients: at onset 175 men with hypogonadism (median age: 64 years). ii) Distribution: by decade. iii) TUD (Nebido-Bayer-Schering) 1000 mg was injected one per 3 months i.m. iv) Prostate volume (PV) appreciated by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm3), Aloka 550. v) Time of analysis: before starting testosterone (T0), after ½ month (T1), 3 (T2), 6 months (T3), 1 (T4), 2 (T5), 3 (T6), 4 (T7), 5 (T8), 6 years (T9). vi) Maximum increment from T0 was noted Δ M %. Average increment was noted ΔA %, and vii) Statistical analysis: Student’s t-test.

Results: i) All average prostatic volume for decade in Table 1.

ii) PV at T0 increases with age, from 17.33 (19–29 years) to 47.41 (80–89 years), P=0.0007. iii) Considering all observations (some at 5/6 years), TUD did not increase PV significantly (average of increment=5.51). iv) Inside a specific decade no significant increased in PV was registered: all P>0.05 (80–89 decades, P=0.057). v) In some patients, especially from 50–79 years, TUD could decrease slightly prostatic volume.

Conclusions: Considering the risk for prostate (in elderly), testosterone undecanoat 1000 mg depot injectable is a safe treatment, even after 3–6 years of administration. Precautions should be accorded to men over 80 years old, after the third administration. Further observation needed.

Article tools

My recent searches

No recent searches.